Thomas A Lanz

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies
    Thomas A Lanz
    CNS Biology, Pfizer Inc, Groton, CT 06340, United States
    J Neurosci Methods 169:16-22. 2008
  2. doi request reprint Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma
    Thomas A Lanz
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Biomarkers 17:524-31. 2012
  3. doi request reprint Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014
    Thomas A Lanz
    Neuroscience Research Unit, Pfizer, Inc, Groton, CT 06340, USA
    J Pharmacol Exp Ther 334:269-77. 2010
  4. ncbi request reprint Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models
    Thomas A Lanz
    CNS Discovery, Pfizer, Inc, Eastern Point Road, Groton, CT 06340, United States
    Biochem Pharmacol 75:1093-103. 2008
  5. ncbi request reprint Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139
    Thomas A Lanz
    Pfizer, Inc, Eastern Point Rd, MS 8220 4183, Groton, CT 06340, USA
    J Pharmacol Exp Ther 319:924-33. 2006
  6. ncbi request reprint Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain
    Thomas A Lanz
    CNS Biology, Pfizer Inc, MS 8220 4183, Eastern Point Road, Groton, CT 06340, USA
    J Neurosci Methods 157:71-81. 2006
  7. ncbi request reprint Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]az
    Thomas A Lanz
    Pfizer Inc, Eastern Point Road, MS 8220 4183, Groton, CT 06340, USA
    J Pharmacol Exp Ther 309:49-55. 2004
  8. doi request reprint Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014
    Michael A Brodney
    Neuroscience Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 21:2637-40. 2011
  9. doi request reprint Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease
    Michael A Brodney
    Neuroscience Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 21:2631-6. 2011
  10. ncbi request reprint Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures
    Thomas A Lanz
    Department of Neurobiology, Pfizer, Inc, Kalamazoo, Michigan, USA
    J Pharmacol Exp Ther 312:399-406. 2005

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies
    Thomas A Lanz
    CNS Biology, Pfizer Inc, Groton, CT 06340, United States
    J Neurosci Methods 169:16-22. 2008
    ..Given the availability of a variety of SPE matrices, we hypothesize that these methods could facilitate plasma antigen retrieval using multiple therapeutic antibody approaches...
  2. doi request reprint Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma
    Thomas A Lanz
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Biomarkers 17:524-31. 2012
    ..Thus, while deficits in BDNF signaling have been implicated in a number of diseases, these data suggest that extracellular concentrations of BDNF may not be a facile biomarker for changes in neurons...
  3. doi request reprint Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014
    Thomas A Lanz
    Neuroscience Research Unit, Pfizer, Inc, Groton, CT 06340, USA
    J Pharmacol Exp Ther 334:269-77. 2010
    ..Potency at Abeta relative to Notch-related endpoints in vitro and in vivo suggests that a therapeutic index can be achieved with this compound...
  4. ncbi request reprint Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models
    Thomas A Lanz
    CNS Discovery, Pfizer, Inc, Eastern Point Road, Groton, CT 06340, United States
    Biochem Pharmacol 75:1093-103. 2008
    ....
  5. ncbi request reprint Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139
    Thomas A Lanz
    Pfizer, Inc, Eastern Point Rd, MS 8220 4183, Groton, CT 06340, USA
    J Pharmacol Exp Ther 319:924-33. 2006
    ..These results suggest that LY-450139 modulates the gamma-secretase complex, eliciting Abeta lowering at high concentrations but Abeta elevation at low concentrations...
  6. ncbi request reprint Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain
    Thomas A Lanz
    CNS Biology, Pfizer Inc, MS 8220 4183, Eastern Point Road, Groton, CT 06340, USA
    J Neurosci Methods 157:71-81. 2006
    ..This isolation method eliminates non-specific binding components from brain extracts and allows for accurate quantitation and robust detection of multiple Abeta peptides in extracts from wild-type animals...
  7. ncbi request reprint Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]az
    Thomas A Lanz
    Pfizer Inc, Eastern Point Road, MS 8220 4183, Groton, CT 06340, USA
    J Pharmacol Exp Ther 309:49-55. 2004
    ..Overall, Abeta in the CSF and not plasma seems to be a better biomarker of brain Abeta reduction; however, the time course of Abeta changes needs to be established in clinical studies...
  8. doi request reprint Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014
    Michael A Brodney
    Neuroscience Medicinal Chemistry, Pfizer PharmaTherapeutics Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 21:2637-40. 2011
    ..Optimization of the FTOC to plasma concentrations at the brain Aβ EC(50) lead to the identification of compound 14f (PF-3084014) which was selected for clinical development...
  9. doi request reprint Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease
    Michael A Brodney
    Neuroscience Medicinal Chemistry, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
    Bioorg Med Chem Lett 21:2631-6. 2011
    ..The therapeutic index between Aβ reductions and changes in B-cell populations were studied for compound 10 h...
  10. ncbi request reprint Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures
    Thomas A Lanz
    Department of Neurobiology, Pfizer, Inc, Kalamazoo, Michigan, USA
    J Pharmacol Exp Ther 312:399-406. 2005
    ..The divergence of the present data from published reports raises the need to examine the conditions necessary to perceive selective Abeta(1-42) reduction by NSAIDs in neuronal tissue...
  11. doi request reprint Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease
    Sherry L La Porte
    Rinat, Pfizer Inc, South San Francisco, CA 94080, USA
    J Mol Biol 421:525-36. 2012
    ..These findings provide novel structural insights into the in vivo conformation of the C-terminus of Aβ40 and the brain Aβ-lowering efficacy that we observed following administration of ponezumab in transgenic mouse models...
  12. doi request reprint Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease
    Robin J Kleiman
    Neuroscience Research Unit, Eastern Point Road, Pfizer Global Research and Development, Groton, CT 06379, USA
    J Pharmacol Exp Ther 336:64-76. 2011
    ..The observed changes in signaling and gene expression are predicted to provide neuroprotective effects in models of Huntington's disease...
  13. ncbi request reprint The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice
    Thomas A Lanz
    Department of Neurobiology, Pharmacia Corporation, 301 Henrietta St, Kalamazoo, MI 49007, USA
    J Pharmacol Exp Ther 305:864-71. 2003
    ..We conclude that CSF and plasma A beta may offer a clinically applicable, mechanism-based biomarker for inhibitors of A beta production...